1990s

The 1990s marked the period in which hepatitis C became an increasingly legible medical and institutional problem. During the decade, improved blood screening reduced transfusion-related transmission, while evidence from hemodialysis, chronic kidney disease, and transplantation redirected attention toward nosocomial spread, extrahepatic disease, and long-term outcomes. The era also laid the groundwork for the later distinction between antibody positivity, active viremia, and sustained virologic response.

From Non-A, Non-B Hepatitis to a Systemic Disease

HCV infection was recognized as the major cause of non-A, non-B hepatitis after the discovery of HCV, and it soon came to be understood as more than a liver disorder. It could induce autoimmune, dermatological, and renal disease, making it relevant to nephrology, dialysis, and transplantation as well as hepatology. This broader framing helped establish HCV as a systemic disease whose consequences extended beyond hepatic inflammation and fibrosis.

The decade also exposed the scale of the public-health burden. HCV ultimately came to be estimated at roughly 3% of the world population, or around 170 million infected individuals, with morbidity, mortality, and associated costs expected to rise even as new infections declined in industrialized countries. The long delay between infection and advanced liver disease meant that the consequences of the epidemic were not confined to the period of transmission: fibrosis could progress to cirrhosis or hepatocellular carcinoma, particularly in the presence of metabolic syndrome or heavy alcohol intake.

Diagnosis, Classification, and the New Laboratory Boundary

The arrival of increasingly sensitive serologic testing changed what could be known about HCV infection. Diagnosis was based on anti-HCV antibodies detected by third-generation enzyme-linked immunosorbent assays, but antibody status alone could not distinguish resolved infection from chronic infection. That distinction depended on detecting HCV RNA in serum with sensitive molecular assays, whose threshold was approximately 15 IU/ml. Chronic infection therefore required both anti-HCV antibodies and detectable HCV RNA.

This antibody-versus-RNA distinction created a new clinical boundary between exposure, recovery, and active infection. It made screening more precise while also turning infection into a sequence of laboratory states that could determine treatment, transplant eligibility, and surveillance. In the emerging clinical framework, chronic infection required not only recognition of prior immune exposure but confirmation that the virus remained present.

Genotyping added another layer of classification. Six HCV genotypes and numerous subtypes were recognized. Genotype 1 was the most prevalent worldwide, with subtype 1b especially common in Japan and Europe and subtype 1a more common in the United States. Genotype 2 appeared in clusters around the Mediterranean, genotype 3a was frequent in the Indian subcontinent and among European intravenous drug users, genotype 4 was historically associated with Egypt and Africa, and genotypes 5 and 6 were less common, with genotype 6 mainly observed in south China. These geographic patterns connected laboratory categories to transmission histories and to differing therapeutic expectations.

Hemodialysis and the Reassessment of Transmission

In hemodialysis, the 1990s revealed how incomplete a transfusion-centered account of HCV transmission had become. Hemodialysis patients were recognized as a high-risk group, partly because transfusions had previously been common, but several observations pointed to continuing transmission within dialysis units. HCV prevalence correlated strongly with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal or home dialysis, and remained substantial among some never-transfused patients.

Blood safety improved dramatically during the decade. The risk of post-transfusion hepatitis C was approximately 0.5% per blood unit in the 1980s, but fell in the United States to around 0.0001%, or one case per million blood units, as donor screening became more sensitive. The growing use of erythropoiesis-stimulating agents for anemia and chronic kidney disease further reduced reliance on transfusion. As transfusion risk receded, infection-control failures within dialysis facilities became a more prominent explanation for new infections.

Later molecular investigations of outbreaks reinforced the importance of the dialysis environment while limiting one specific explanation. Across 20 studies of newly diagnosed HCV-positive hemodialysis patients, no single transmission route was conclusively established, but all studies implicated probable failures in infection-control procedures. In 18 of the 20 studies, some or all newly infected patients had not shared a dialysis machine with the source patient. The internal machine circuit therefore appeared to play, at most, a small role, while handling practices and the wider clinical environment became the central targets of prevention.

This evidence shaped policy. The KDIGO workgroup concluded that dedicated dialysis machines for HCV-infected patients were not recommended. It also found no convincing evidence that placing HCV-infected patients in separate wards protected others when compared with strict infection-control procedures. Large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study, found that isolation did not protect against transmission after adjustment for relevant confounders. The decisive preventive principle was not segregation but rigorous infection control.

Chronic Disease, Dialysis, and Transplantation

HCV-related liver disease in long-term dialysis patients was often clinically quiet. Fatigue, asthenia, and cognitive impairment were difficult to attribute specifically to HCV because they were common in dialysis patients regardless of serologic status. Biochemical abnormalities could nevertheless appear: serum transaminases and gamma-glutamyl transpeptidase were frequently elevated, and a large United States cohort of 13,664 long-term dialysis patients showed an independent relationship between anti-HCV seropositivity and serum alkaline phosphatase activity. HCV-positive patients also had higher intact parathormone levels, 422 ± 423 versus 338 ± 356 pg/ml, an observation linked to hepatic osteodystrophy. Cirrhosis remained relatively infrequent in Western dialysis registries, occurring in approximately 1.5% to 2% of patients.

The effects were not limited to measurable liver injury. In a study of 165 regular dialysis patients, 83 of whom were anti-HCV positive, HCV positivity was independently associated with a lower mental component score on the SF-36 quality-of-life instrument, with a coefficient of –3.423. No association was found with the physical component score. Depression, concern about long-term health, fatigue, cognitive impairment, and the burdens of dialysis formed an overlapping field of illness experience in which the biological infection and its interpretation could not be cleanly separated.

Transplantation made the time dimension of HCV especially visible. Studies with follow-up shorter than ten years often failed to detect significant survival differences between HCV-positive and HCV-negative kidney recipients, whereas most later studies with extended follow-up showed worse patient survival among HCV-positive recipients. The contrast suggested that liver disease and other HCV-related complications could emerge slowly or late after transplantation. A meta-analysis of eight clinical trials involving 6,365 patients found adjusted relative risks of 1.79 for patient mortality and 1.56 for graft loss in HCV-infected recipients; increased mortality was partly liver-related, while graft loss was associated in part with HCV-related renal disease.

The 1990s thus became a baseline against which later therapeutic and transplant policies were judged. Immunosuppression used in that era, including azathioprine, cyclosporine, high-dose steroids, and sometimes lymphocyte-depleting induction therapy, could increase HCV replication compared with RNA concentrations during dialysis. Although later studies disagreed about the speed of liver-fibrosis progression after kidney transplantation, approximately 20% of some HCV-positive recipients developed severe fibrosis, and HCV could contribute to fibrosing cholestatic hepatitis, cirrhosis, hepatocellular carcinoma, glomerulopathies, and impaired allograft survival.

The Decade’s Legacy in Treatment and Allocation

The medical infrastructure established around HCV in the 1990s prepared the way for treatment based on virologic measurement. By the following period, pegylated interferon and ribavirin could produce sustained virologic response in more than half of patients with chronic infection, while direct-acting antiviral drugs were being developed against viral proteases, polymerases, and other targets. The significance of the 1990s lies less in a single curative regimen than in the creation of the diagnostic and epidemiological categories that made response measurable and treatment rational.

Those categories also entered transplant decision-making. Candidates for kidney transplantation were screened for anti-HCV antibodies and active viremia, and active infection required staging of liver disease, with liver biopsy remaining the gold standard during pretransplant evaluation. Patients with established or decompensated cirrhosis were directed toward the liver transplant team for possible simultaneous liver-kidney transplantation. Patients on waiting lists required continuing surveillance because long waits could permit disease progression; in one group, 8 of 13 patients, or 62%, showed worsening liver histology while waiting.

The decade’s shift from transfusion safety to institutional prevention and from symptom-based judgment to molecular classification also influenced the use of donor organs. HCV-positive donor kidneys could transmit infection, but their use was considered against the dangers of prolonged dialysis and organ scarcity. HCV-infected end-stage renal disease patients who could not receive, refused, or did not respond to interferon-based therapy might still fare better with transplantation than by remaining on dialysis. The 1990s therefore left a complicated inheritance: HCV became more precisely identified and more tightly managed, but its status continued to shape access to machines, waiting lists, antiviral therapy, and donated organs.